Director, Business Development & Acquisitions, AbbVie
David Tannin is director of business development and acquisitions at AbbVie, where he leads licensing, partnership and M&A transactions across multiple therapeutic areas. He has supported business development efforts in neuroscience and ophthalmology and most recently has focused on helping to build AbbVie’s metabolic disease portfolio. David brings more than a decade of experience in biopharmaceutical business development, corporate strategy and transaction execution. Prior to AbbVie, David held corporate development roles at Pfizer and Global Blood Therapeutics, supporting transactions ranging from early-stage research collaborations to global licensing agreements and acquisitions. Earlier in his career, he advised biotechnology and pharmaceutical companies on corporate strategy, business development and transactions. David holds a Master of Science in management of drug development from the University of Southern California and a B.S. in neuroscience from the University of California, Santa Barbara.